more

Related Articles

Ziff Davis Buys Another Website
Actavis to Buy Warner Chilcott To Expand in Women’s Health
PPG Expands Aerospace Coatings Business with Deft Deal
Marissa Mayer Buys Tumblr for $1.1B in Yahoo’s Biggest Deal Since 1999
Aridis Pharma Picks Up Kenta Biotech’s Anti-Infection Products

SLIDESHOW

The M&A Scene: CEO Leadership
Dealmakers gathered at the Harvard Club in New York on May 7 as part of ACG NY's CEO Leadership event. Peter Gonye, a co-leader within Spencer Stuart's private equity practice in North America was the keynote speaker. Panelists included M. Tatum Pursell, senior adviser, Unlimited Horizons; Tony Ecock, general partner, Welsh Carson Anderson & Stowe; Jim Follett, former CEO of Authentic Response Inc.; Doron Grosman, operating partner, Court Square Capital; and Joelle Marquis, partner, Arsenal Capital.

Watercooler

Far Cry from the Glory Days
These days, big buyers are more likely to co-invest with limited partners

Dealmakers

Time Inc. -Meredith Pairing Would Have Been Too Complicated, Says Jeff Bewkes in Keynote
The Time Warner chairman hints there may be a future deal for the spun-off magazine business, maybe even with Meredith

Columns

The Buyside:
Trench Dealfare
Strategic players in the aerospace and defense sector look to offset losses by remaining on the hunt for targets

Healthcare: Perrigo Purchases Rosemont Pharmaceuticals for $283M

Perrigo’s second deal this month expands its liquid medications portfolio

By ALLISON COLLINS
February 11, 2013

Allegan, Mich.-based pharmaceutical company Perrigo Co. (Nasdaq: PRGO) is buying Rosemont Pharmaceuticals Ltd. for about $283 million.

Rosemont, based in Leeds, U.K., makes specialty and generic prescription pharmaceutical company that makes oral, liquid products.

The deal will broaden Perrigo’s consumer product portfolio, and aligns with its goal of adding more liquid medications its offerings and expanding its U.K. portfolio.

In February, Perrigo announced it would buy pet medication company Velcera for $160 million and in December the company completed a $45 million deal for Cobrek Pharmaceuticals Inc. 

 

For more information on related topics, visit the following: